Development of arsenic trioxide sustained-release pellets for reducing toxicity and improving compliance

References

• Swindell EP, Hankins PL, Chen H, et al. Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes. Inorg Chem. 2013;52(21):12292–12304.
   PubMed Web of Science ®Google Scholar
• Ades L, Thomas X, Bresler AG, et al. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. Haematologica. 2018;103(12):2033–2039.
   PubMed Web of Science ®Google Scholar
• Case 28-2014: a man with a rash, headache, fever, nausea, and photophobia. N Engl J Med. 2014;371(23):2238–2239.
   Google Scholar
• Zhu HH, Hu J, Lo-Coco F, et al. The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood. 2019;134(7):597–605.
   PubMed Web of Science ®Google Scholar
• Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J. 2015;5:e304.
   PubMed Web of Science ®Google Scholar
• Zhou J, Meng R, Li X, et al. The effect of arsenic trioxide on QT interval prolongation during APL therapy. Hematol J. 2005;90(9):1277–1279.
   Google Scholar
• Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21(19):3609–3615.
   PubMed Web of Science ®Google Scholar
• Zhao WL, Chen SJ, Shen Y, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies. Leuk Lymphoma. 2001;42(6):1265–1273.
   PubMed Web of Science ®Google Scholar
• Rojewski MT, Baldus C, Knauf W, et al. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br J Haematol. 2002;116(3):555–563.
   PubMed Web of Science ®Google Scholar
• Zhou J, Meng R, Sui X, et al. Effects of administration styles of arsenic trioxide on intracellular arsenic concentration, cell differentiation and apoptosis. Haematologica. 2005;90(9):1277–1279.
   PubMed Web of Science ®Google Scholar
• Zhou J, Meng R, Yang BF. Comparing two arsenic trioxide administration methods in APL therapy. Chin Med J. 2004;117(9):1411–1413.
   PubMed Web of Science ®Google Scholar
• Jiang H, Liang GW, Huang XJ, et al. Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. Leuk Res. 2015;39(12):1319–1324.
   PubMed Web of Science ®Google Scholar
• Shi Q, Ju M, Zhu X, et al. Pharmacokinetic properties of arsenic species after intravenous and intragastrical administration of arsenic trioxide solution in cynomolgus macaques using HPLC-ICP-MS. Molecules. 2019;24(2):241.
   Web of Science ®Google Scholar
• da Rosa FC, Buque Pardinho R, Schultz Moreira ME, et al. In vitro stability of arsenic trioxide-liposome encapsulates for acute promyelocytic leukemia treatment. Leuk Res. 2019;76:11–14.
   PubMed Web of Science ®Google Scholar
• Akhtar A, Ghali L, Wang SX, et al. Optimisation of folate-mediated liposomal encapsulated arsenic trioxide for treating HPV-positive cervical cancer cells in vitro. Int J Mol Sci. 2019;20(9):2156.
   Web of Science ®Google Scholar
• Song X, Wang J, Xu Y, et al. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: inhibition effects enhanced and side effects reduced. Colloids Surf B Biointerfaces. 2019;180:110–117.
   PubMed Web of Science ®Google Scholar
• Hoonjan M, Sachdeva G, Chandra S, et al. Investigation of HSA as a biocompatible coating material for arsenic trioxide nanoparticles. Nanoscale. 2018;10(17):8031–8041.
   PubMed Web of Science ®Google Scholar
• Peng Y, Zhao Z, Liu T, et al. Smart human-serum-albumin-As2O3 nanodrug with self-amplified folate receptor-targeting ability for chronic myeloid leukemia treatment. Angew Chem Int Ed Engl. 2017;56(36):10845–10849.
   PubMed Web of Science ®Google Scholar
• Torka P, Al Ustwani O, Wetzler M, et al. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia. Blood Rev. 2016;30(3):201–211.
   PubMed Web of Science ®Google Scholar
• Au WY, Kumana CR, Lee HK, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood. 2011;118(25):6535–6543.
   PubMed Web of Science ®Google Scholar
• Firkin F. Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre study. Intern Med J. 2012;42(8):948–952.
   PubMed Web of Science ®Google Scholar
• Au WY, Kwong YL. Arsenic trioxide: safety issues and their management. Acta Pharmacol Sin. 2008;29(3):296–304.
   PubMed Web of Science ®Google Scholar
• Au WY, Li CK, Lee V, et al. Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients. Pediatr Blood Cancer. 2012;58(4):630–632.
   PubMed Web of Science ®Google Scholar
• Kumana CR, Au WY, Lee NS, et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol. 2002;58(8):521–526.
   PubMed Web of Science ®Google Scholar
• Liu Y, He P, Cheng X, et al. Long-term outcome of 31 cases of refractory acute promyelocytic leukemia treated with compound realgar natural indigo tablets administered alternately with chemotherapy. Oncol Lett. 2015;10(2):1184–1190.
   PubMed Web of Science ®Google Scholar
• Xu H-H, Ma Z-C, Shi Q-L, et al. Synergistic effect and different toxicities of adjuvant components of realgar–indigo naturalis formula. Chin Herb Med. 2018;10(2):137–144.
   Web of Science ®Google Scholar
• Gill H, Kumana CR, Yim R, et al. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: a 5-year prospective study. Cancer. 2019;125(17):3001–3012.
   PubMed Web of Science ®Google Scholar
• Yang MH, Wan WQ, Luo JS, et al. Multicenter randomized trial of arsenic trioxide and realgar–indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: interim results of the SCCLG-APL clinical study. Am J Hematol. 2018;93(12):1467–1473.
   PubMed Web of Science ®Google Scholar
• Dong L, Yang F, Zhu Z, et al. Preparation, characterization and pharmacokinetics evaluation of the compound capsules of ibuprofen enteric-coated sustained-release pellets and codeine phosphate immediate-release pellets. AAPS PharmSciTech. 2018;19(7):3057–3066.
   PubMed Web of Science ®Google Scholar
• Cui Y, Zhang Y, Tang X. In vitro and in vivo evaluation of ofloxacin sustained release pellets. Int J Pharm. 2008;360(1–2):47–52.
   PubMed Web of Science ®Google Scholar
• Xu M, Liew CV, Heng PWS. Evaluation of the coat quality of sustained release pellets by individual pellet dissolution methodology. Int J Pharm. 2015;478(1):318–327.
   PubMedGoogle Scholar
• Asada T, Yoshihara N, Ochiai Y, et al. Formulation of a poorly water-soluble drug in sustained-release hollow granules with a high viscosity water-soluble polymer using a fluidized bed rotor granulator. Int J Pharm. 2018;541(1–2):246–252.
   PubMedGoogle Scholar
• Nasiri MI, Yousuf RI, Shoaib MH, et al. Investigation on release of highly water soluble drug from matrix-coated pellets prepared by extrusion–spheronization technique. J Coat Technol Res. 2016;13(2):333–344.
   Web of Science ®Google Scholar
• Wang L, Wang J, Lin X, et al. Preparation and in vitro evaluation of gliclazide sustained-release matrix pellets: formulation and storage stability. Drug Dev Ind Pharm. 2010;36(7):814–822.
   PubMed Web of Science ®Google Scholar
• Li G, Zhao M, Su X, et al. Preparation and in vitro–in vivo evaluation of intestinal retention pellets of berberine chloride to enhance hypoglycemic and lipid-lowing efficacy. Asian J Pharm Sci. 2019;14(5):559–568.
   PubMed Web of Science ®Google Scholar
• Zhang X, Tang X, Yang R. Development of a tamsulosin hydrochloride controlled-release capsule consisting of two different coated pellets. Drug Dev Ind Pharm. 2009;35(1):26–33.
   PubMed Web of Science ®Google Scholar
• Zhang L, Jiang P, Liu J. Novel sustained-release of propafenone through pellets: preparation and in vitro/in vivo evaluation. Int J Mol Sci. 2014;15(9):15503–15511.
   PubMed Web of Science ®Google Scholar
• Muley S, Nandgude T, Poddar S. Extrusion–spheronization a promising pelletization technique: in-depth review. Asian J Pharm Sci. 2016;11(6):684–699.
   Web of Science ®Google Scholar
• Garekani HA, Dolatabadi R, Akhgari A, et al. Evaluation of ethylcellulose and its pseudolatex (Surelease) in preparation of matrix pellets of theophylline using extrusion–spheronization. Iran J Basic Med Sci. 2017;20(1):9–16.
   PubMed Web of Science ®Google Scholar
• Fu J, Wang X, Xu L, et al. Preparation and in vitro–in vivo evaluation of double layer coated and matrix sustained release pellet formulations of diclofenac potassium. Int J Pharm. 2011;406(1–2):84–90.
   PubMed Web of Science ®Google Scholar
• Han X, Wang L, Sun Y, et al. Preparation and evaluation of sustained-release diltiazem hydrochloride pellets. Asian J Pharm Sci. 2013;8(4):244–251.
   Google Scholar
• He H, Shi B, Cai C, et al. Preparation of lovastatin matrix sustained-release pellets by extrusion–spheronization combined with microcrystal dispersion technique. Arch Pharm Res. 2011;34(11):1931–1938.
   PubMed Web of Science ®Google Scholar
• Yadav D, Survase S, Kumar N. Dual coating of swellable and rupturable polymers on glipizide loaded MCC pellets for pulsatile delivery: formulation design and in vitro evaluation. Int J Pharm. 2011;419(1–2):121–130.
   PubMedGoogle Scholar
• Ni J, Chen G, Shen Z, et al. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia. Chin Med J (Engl). 1998;112(5):27–30.
   Google Scholar
• Fei W, Zhang Y, Han S, et al. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma. Int J Pharm. 2017;519(1–2):250–262.
   PubMed Web of Science ®Google Scholar
• Xiao X, Liu Y, Guo M, et al. pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo. J Biomater Appl. 2016;31(1):23–35.
   PubMed Web of Science ®Google Scholar